Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is at least 18-years of age.~2. Clinical and imaging diagnosis of a symptomatic Isolated cavernous malformation or Familial cavernous malformation~3. MRI Imaging Grade Type I or Type II (see Table 1)~4. Patient is considered a candidate for surgical resection of their cavernous malformation~5. Written and informed consent obtained prior to the study enrollment.~6. Negative pregnancy test at time of enrollment for women of child-bearing potential.~7. Heart rate greater than 50 beats per minute~8. Systolic blood pressure \> 90 mmHg~Exclusion Criteria:~1. Subject is less than 18-years of age.~2. History of allergy to propranolol or other beta blockers.~3. Patient is already taking another beta blocker for cardiac indications.~4. History of asthma presently requiring any active treatment (oral medications or inhalers).~5. History of cardiac dysfunction (as defined by the New York Heart Association Functional Classification grade II, III or IV).~6. Heart rate \< 50 beats per minute~7. Systolic blood pressure \< 90 mmHg~8. History of diabetes and currently on any anti-hyperglycemic medication.~9. Pregnant and lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment group (Type: EXPERIMENTAL): A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
- Control Group (Type: OTHER): A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).